Stock Market Today, April 16: Hims & Hers Health Jumps on FDA Review of Compounded Peptide Therapies

By Josh Kohn-Lindquist – Apr 16, 2026 at 4:57PM ESTExpandNYSE: HIMSHims & Hers HealthToday's Change(11.28%) $2.74Current Price$27.03Key Data PointsMarket Cap$5.5BDay's Range$24.77 - $27.8152wk Range$13.74 - $70.43Volume2.5MAvg Vol35MGross Margin60.86%Hims & Hers Health (HIMS +11.28%), a consumer-focused telehealth platform offering prescription and non-prescription health products, closed Thursday at $26.98, up 11.07%. The stock moved higher as investors reacted to the FDA’s decision to review compounded peptide therapies. Trading volume reached 74.6 million shares, about 111% above its three-month average of 35.3 million shares. Hims & Hers Health IPO'd in 2019 and has grown 175% since going public.How the markets moved todayS&P 500 added 0.23% to finish Thursday’s session at 7,039, while the Nasdaq Composite rose 0.36% to close at 24,103. Across telehealth and online health services, peers were mixed: Teladoc Health closed at $5.82 (up 5.05%), while American Well ended at $6.05 (down 3.04%).What this means for investorsHims & Hers Health stock rose 11% today following Health and Human Services Secretary Robert Kennedy Jr.’s announcement that the Food and Drug Administration may remove 12 peptides from its Category 2 restrictions. This decision could clear a path for companies like HIMS to offer these peptides to the public. Currently, this is more of a “gray” market.Early in 2025, HIMS purchased a peptide manufacturing facility in California, so it seems well-positioned to benefit should the peptide therapies receive full regulatory clearance. Following the news, a Bank of America analyst reiterated their neutral rating on HIMS stock, but raised their price target from $21 to $25, as they believed the company’s manufacturing capabilities could also be converted from GLP-1’s to peptides, adding an additional tailwind.Read NextApr 2, 2026 •By Parkev Tatevosian, CFAShould You Buy Hims Stock Today?Mar 25, 2026 •By Motley Fool StaffSurging Oil Prices Spark Market JittersMar 17, 2026 •By Brett SchaferTop 2 S&P 500 Stocks to Watch This Week After Hims & Hers Stock's Surprise MoveApr 16, 2026 •By Prosper Junior Bakiny3 Under-the-Radar Healthcare Stocks Worth Adding to Your WatchlistApr 16, 2026 •By Leo SunWhy AbbVie Is a No-Brainer Stock to Buy on the DipApr 16, 2026 •By Eric TrieStock Market Today, April 16: Robinhood Slips as Schwab’s Crypto Push Raises New CompetitionAbout the AuthorJosh Kohn-Lindquist is a contributing Motley Fool stock market analyst covering consumer goods, industrials, and technology stocks. Previously, Josh was a senior mutual fund accountant at Gemini Fund Services. He holds a bachelor’s degree in business management from the University of South Dakota.TMFJorykoX@JorykoliStocks MentionedHims & Hers HealthNYSE: HIMS$27.03(+11.28%)+$2.74*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.